Sight Sciences, Inc. (SGHT)
NMS · Healthcare · Medical Devices
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About Sight Sciences, Inc.
Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segments, Surgical Glaucoma and Dry Eye. It offers OMNI, a surgical system family of products, such as OMNI Ergo for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and OMNI EDGE, an implant-free and minimally invasive glaucoma surgery technology. The company also provides SION, a bladeless and manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork; and TearCare system, a proprietary, interventional, dry eye device designed to melt and facilitate the comprehensive removal of meibomian gland obstructions and restore gland functionality and healthy oil production for adult patients with evaporative dry eye disease due to meibomian gland disease when used in conjunction with manual expression of the meibomian glands for ophthalmologists and optometrists. It serves hospitals, medical centers, and eyecare professionals through sales representatives and distributors. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 19.6M | 19.9M | 20.4M | 19.7M |
| Gross Profit | 16.6M | 17.2M | 17.8M | 17.0M |
| Operating Income | -11.7M | -7.9M | -3.7M | -12.4M |
| Net Income | -11.9M | -8.2M | -4.2M | -13.0M |
| Diluted EPS | $-0.23 | $-0.16 | $-0.08 | $-0.24 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 71.3M | 81.1M | 79.9M | 77.4M |
| Gross Profit | 59.0M | 69.2M | 68.3M | 66.7M |
| Operating Income | -84.0M | -57.3M | -50.5M | -37.1M |
| Net Income | -86.2M | -55.5M | -51.5M | -38.4M |
| Diluted EPS | $-1.80 | $-1.14 | $-1.03 | $nan |